pipelin product portfolio solidifi
updat forecast estim jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim jan
price data jan
rate updat jan
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
regain foot one three major
cardiac devic maker left acquisition-rel
oper mishap earlier manag team behind
although boston necessarili beat market
new innov firm remain tough competitor
clean intern cultur issu sometim led unforc
error boston part ceo michael mahoney focus
firm introduc meaning innov leverag boston
histor formid sale market resourc
mahoney shift boston away earlier relianc
tradit cardiac rhythm manag stent busi
larg matur point focu new
technolog boston tap novel platform includ
eluvia stent peripher use subcutan
defibril left atrial appendag closur atrial fibril
product even market face slower growth boston
bolster signific presenc consist introduc new
product exampl boston maintain strong posit
drug-coat coronari stent
develop
transcathet mitral valv repair technolog -- build
boston footprint cardiac vascular market despit
trail cardiac rhythm manag boston remain
game recent launch compar mri-saf
devic quadripolar lead
remain favor boston effort return
transcathet aortic valv market lotu devic launch
new acur tavr product addit male
urolog portfolio
long view moatiest part am busi big
question whether boston wide-rang presenc across devic
categori enough maintain posit especi
competitor includ abbott seek
consolid order solidifi place hospit
vendor would surpris competit medic
technolog compani may eye boston
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
produc less-invas medic devic insert
human bodi small open cut manufactur
product use angioplasti blood clot filtrat cardiac rhythm
diseas upper gastrointestin tract test treatment incontin
firm market devic healthcar profession institut
global foreign sale account nearli half firm total sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
modestli rais fair valu estim
per share reflect slightli higher expect
watchman left atrial appendag closur devic return
lotu tavr europ increas adopt
s-icd continu hold rel optimist project
boston growth beyond explicit forecast period
base firm pipelin promis technolog
includ acur tavr eluvia drug-coat stent
peripher use new electrophysiolog navig
platform midterm expect averag annual
top-lin growth fuel primarili
cardiovascular med-surg segment addit
btg manag effort streamlin oper
enhanc effici taken hold forecast
increas roughli basi point adjust oper
margin sell market cost risen
last year order support plan product
launch howev expect slightli moder
come year new product see greater
base higher averag volatil cash flow
on-go exposur product liabil claim rate
uncertainti high
bear-cas scenario place share
assum long-term data boston watchman devic
diminish demand left atrial appendag closur
devic lotu transcathet valv unabl gain
substanti ground edward
tavr market scenario includ slow eros
boston coronari stent franchis subcutan
adopt fall short expect assum
clinic efficaci ablat atrial fibril
disappoint urolog sling penil implant revenu
growth slow cost share increas anem
perform higher-margin busi boston
oper margin would match histor adjust
margin
bull case would rais fair valu estim
per share assum boston see robust uptak
watchman penil implant catheter-bas ablat
lotu valv new intervent oncolog
platform averag annual revenu growth exceed
next five year thank disciplin
exclud charg
contrast key cardiac devic rival st
jude part abbott enjoy wide moat boston
sport narrow moat reflect firm fallen
behind technolog innov boston
becom laggard st jude step
technolog front thank unwieldi integr
guidant number product recal warn letter
 food drug administr oper
dysfunct sizabl debt load boston unabl
financi
constrain compet acquisit
manag turn time ceo michael
mahoney steadi ship focus organ
pump innov
innov found
boston narrow moat remain firmli root intang
asset boston benefit cach patent cover
variou product although intellectu properti
necessarili lock competitor year
pharmaceut asset shield firm
competit base primarili price boston along
medic devic compani aggress defend
intellectu properti intellectu properti right
violat result sale injunct
competitor requir stop sell product
near midterm pose setback peer compani
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fragment hospit less abl exert
bargain power cardiac devic maker
note coronari stent market seem
stabl three competitor field -- price
declin older product becom pronounc
four player game may one reason
johnson johnson exit coronari stent market
late
firm competit stand solid base intern
develop product well novel acquir technolog
boston necessarili first-to-market key
emerg technolog set drive growth
cardiac market next five year think
innov differenti enough allow firm
market
manag left atrial appendag closur devic
drug-coat peripher balloon addit think
purchas rival st jude medic abbott could lead
weaker pipelin abbott continu nurtur st
jude cultur innov final note threat
new entrant remain low especi consid
regulatori approv
gain
must revisit draw board redesign product
way infring exist patent
longer term howev devic manufactur usual
invent way around patent
boston also enjoy extens network relationship
practition -- anoth basi moat boston still
own signific footprint stent electrophysiolog
endoscopi urolog neuromodul intervent
cardiolog radiolog devic stent busi strike
us least moati consid quick learn curv
gener substitut brand howev
devic area gener steeper
learn curv requir greater invest
practition use well make less like devic
use interchang competit brand
final cardiac medic devic industri structur
way make highli unlik new market
entrant could come edg boston small
start-up like purchas bigger fish
technolog pan oligopoli strengthen
boston custom base rel
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
oboston remain one top player come
intellectu properti medic technolog
arena bode well abil innov
enough keep rival
oboston breadth product emphasi
differenti put compani firm foot
supplier hospit
oboston coronari stent busi less moati
cardiac rhythm manag segment
oboston busi unlik return double-
digit growth long physician remain hamper
current implant guidelin dearth
diagnost test accur identifi sudden
oboston recent acquisit put firm
leadership role sever nich market
includ leadless icd bronchialthermoplasti
oboston like second third market
key emerg technolog drive growth
cardiac devic next five year
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
increas debt leverag acquir
new product reduc debt
increas late accommod
impend acquisit btg septemb
compani held million cash compar
billion long-term debt expect firm exit
year debt/ebitda around time firm
financ billion plan acquisit btg primarili
cash hand addit debt boston key debt
matur next year includ billion
due anoth million earli
firm issu billion due proce
primarili earmark buy back million debt near
matur compani suspend share repurchas
program help de-lever pay dividend
howev surpris share repurchas
restart near midterm
base higher-than-averag volatil cash flow
on-going exposur product liabil claim rate
boston scientif uncertainti high think
manag put boston trail qualiti
alway face possibl devic defect product
recal exampl boston reach tail end
settlement transvagin mesh product firm
set asid nearli billion cover liabil relat
matter think boston may need increas
reserv base number claimant
recent settlement amount thank healthcar reform
hurdl secur reimburs technolog
add-on payment risen boston need invest
clinic studi demonstr superior outcom
and/or cost save order establish reimburs
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
think boston stewardship standard base current
ceo michael mahoney influenc boston perform
last three year mahoney bring impress devic
experi johnson johnson focus
repopul firm pipelin re-energ firm
focu meaning innov think new team
helm provid boston clean slate like
capit alloc decis
shareholder-friendli especi contrast former ceo
jim tobin expens pursuit guidant
mahoney approach alloc invest
much prudent eye disciplin manner
pleas tuck-in acquisit adjac field
strengthen boston portfolio key therapeut area
instanc boston acquisit securu medic
make thermal monitor equip good fit
boston cardiac ablat cathet firm also
acquir sadra medic lotu tavr symeti acur
tavr soon integr btg intervent
ceo/chairman board/
repres date owner name posit common share held report holder issuer
fidel manag research compani
capit research manag compani
share
fund
share
fund
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
rule unconstitut district court
near-term impact fundament dec
dec judg reed connor northern district
texa issu rule effect declar patient
protect afford act
unconstitut assum littl chang
compani cover healthcar sector
near term rule like make way
appeal process surpris see
case third appear make front
 suprem court potenti timelin final
basi decis find root congress
elimin shared-respons financi penalti
accompani passag tax cut job act
late last year short judg connor found individu
mandat essenti insever provis
congress decis elimin enforc
tax penalti law render entireti
legisl unconstitut logic follow
 suprem court decis upheld
constitut congress power taxat
view healthcar provid sector at-risk
stem chang prevail healthcar
legisl whether chang individu coverag
roll-back medicaid expans higher uninsur
rate unequivoc equat pressur hospit margin
payer perspect trade-off littl less clear
although medicaid-focus insur like feel
bulk enrol loss
intend make chang moat rate fair
valu estim result decis continu
monitor case make way appel
court come month outcom timelin
uncertain make meaning chang
assumpt earli day addit wildcard
potenti legisl action muddi
ultim financi penalti carri
insur coverag set end jan
understand feder govern intend
maintain statu quo appeal process
insur alreadi lock rate propos
earliest like see potenti effect
rule premium polici offer slate
open enrol season
oncolog btg purchas chang fve
first blush think boston impend acquisit
 -base btg make strateg sens though purchas
price isnt bargain perspect leav
fair valu unchang rais estim
key growth driver larg off-set
purchas btg boston offer price reflect
premium btg share trade
incorpor optimist
project watchman well greater adopt
s-icd practition impend return
lotu transcathet aortic valv european market
current give boston narrow econom moat
rate think time revisit firm merit
potenti moat upgrad base strength
portfolio new product pipelin
think one biggest opportun btg offer
path boston establish footprint intervent
oncolog fairli new subspecialti offer fast
growth think technolog dovetail well
boston expertis intervent procedur image-
guid vascular intervent well exist
relationship liver kidney pulmonari specialist
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
patient world-wide addit vigil surveil
practition along better diagnost tool
translat long-term growth patient favor
clinic data behind af ablat hospit concern
readmitt offer condit conduc sustain
long-term growth market sinc boston
made concert invest area sinc
deliv annual growth averag boston recent
acquisit cryoablat technolog round
portfolio bolster firm strong posit
launch
new wavewrit
neuromodul technolog deliv strong double-
digit growth second quarter spinal cord stimul
recent seen burst innov expect boston
right mix fortun recent rule
intellectu properti doesnt seem like hamper
boston abil commerci wavewrit platform
main area weak boston remain cardiac
rhythm manag segment dont expect
matur market grow much beyond mid-singl digit
watch care mainli medtron
aggress approach hospit risk-
share contract system think medtron
strategi hold potenti shift basi competit
insul devic full brunt competit product
launch recogn boston current compet
without full suit resynchron devic
could explain anem growth suspect
medtron risk-shar contract may also materi
exampl
boston pick number smaller acquisit
attract price opinion btg larger
expens weve seen ceo mike
mahoney tenur far howev consid well
smaller integr gone boston return
consist produc innov product anticip
firm abl take btg key device-bas
platform reach wider base global custom btg
also pharmaceut busi doesnt fit
neatli boston core compet despit
suspect attract margin would favor
boston sell busi reinvest proce
toward minimally-invas product line
boston scientif outpac market
chang fve jul
quarter perform consist
expect slight adjust model werent
enough move needl leav fair valu
strength across segment gener grew
high singl digit organ year year
continu project above-market top-line growth
boston along roughli basi point oper
margin improv
like boston push area
patient typic undertr common
strategi among cardiac devic maker recogn
boston quit savvi select technolog
target go exampl prior firm
miss electrophysiolog market
grow teen market tap larg
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
